Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aligos Therapeutics, Inc.

8.43
-0.1800-2.09%
Volume:36.07K
Turnover:306.75K
Market Cap:51.86M
PE:-0.89
High:8.72
Open:8.60
Low:8.30
Close:8.61
52wk High:46.80
52wk Low:3.76
Shares:6.15M
Float Shares:3.00M
Volume Ratio:0.99
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.4728
EPS(LYR):-20.9448
ROE:-87.74%
ROA:-40.30%
PB:0.51
PE(LYR):-0.40

Loading ...

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire
·
Yesterday

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Yesterday

Aligos Therapeutics (ALGS) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Oct 28

Aligos Therapeutics’ Promising Hepatitis B Study: A Potential Game-Changer?

TIPRANKS
·
Oct 28

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

TIPRANKS
·
Oct 17

Aligos Therapeutics Receives Usan Council Approval for Pevifoscorvir Sodium as Nonproprietary Name for Alg-000184

THOMSON REUTERS
·
Oct 16

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

GlobeNewswire
·
Oct 16

H.C. Wainwright Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)

TIPRANKS
·
Oct 15

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

GlobeNewswire
·
Oct 14

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

GlobeNewswire
·
Oct 07

Aligos Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 12

Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target

TIPRANKS
·
Sep 12

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

GlobeNewswire
·
Sep 04

Aligos Therapeutics Strengthens Senior Leadership Team With the Appointment of RamÓN Polo as Senior Vice President, Head of Global Regulatory Affairs

THOMSON REUTERS
·
Aug 20

Press Release: Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Dow Jones
·
Aug 20

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 15

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-Supreme Study of Alg-000184 in Subjects With Chronic Hbv Infection

THOMSON REUTERS
·
Aug 13

Aligos Therapeutics Inc - Interim Data for Phase 2 Study Projected in 2026

THOMSON REUTERS
·
Aug 13

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

GlobeNewswire
·
Aug 13

Aligos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 07